SLC5A2 and lupus nephritis: Although based on a small number of patients, SGLT2 inhibitors showed a relevant but not statistically significant antiproteinuric effect in both nephritides (−43% (95% CI −50 to 1) in lupus nephritis and −31% (95% CI −53 to 18) in patients with ANCA-associated vasculitis.